EP3331571A4 - COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS - Google Patents

COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS Download PDF

Info

Publication number
EP3331571A4
EP3331571A4 EP16804107.7A EP16804107A EP3331571A4 EP 3331571 A4 EP3331571 A4 EP 3331571A4 EP 16804107 A EP16804107 A EP 16804107A EP 3331571 A4 EP3331571 A4 EP 3331571A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
viral infections
treat viral
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16804107.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3331571A1 (en
Inventor
Stephen R. Quake
Jianbin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agenovir Corp
Original Assignee
Agenovir Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenovir Corp filed Critical Agenovir Corp
Publication of EP3331571A1 publication Critical patent/EP3331571A1/en
Publication of EP3331571A4 publication Critical patent/EP3331571A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
EP16804107.7A 2015-05-29 2016-05-27 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS Withdrawn EP3331571A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562168259P 2015-05-29 2015-05-29
US201562168262P 2015-05-29 2015-05-29
PCT/US2016/034606 WO2016196273A1 (en) 2015-05-29 2016-05-27 Compositions and methods to treat viral infections

Publications (2)

Publication Number Publication Date
EP3331571A1 EP3331571A1 (en) 2018-06-13
EP3331571A4 true EP3331571A4 (en) 2019-04-10

Family

ID=57441664

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16804107.7A Withdrawn EP3331571A4 (en) 2015-05-29 2016-05-27 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS

Country Status (4)

Country Link
EP (1) EP3331571A4 (enExample)
JP (1) JP2018516983A (enExample)
CA (1) CA3000189A1 (enExample)
WO (1) WO2016196273A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
EP4079847A1 (en) 2014-07-30 2022-10-26 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
GB2543873A (en) * 2015-05-29 2017-05-03 Agenovir Corp Compositions and methods for cell targeted HPV treatment
IL294014B2 (en) 2015-10-23 2024-07-01 Harvard College Nucleobase editors and uses thereof
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
SG11201903089RA (en) 2016-10-14 2019-05-30 Harvard College Aav delivery of nucleobase editors
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
EP3592381A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Cancer vaccine
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
GB2575930A (en) 2017-03-23 2020-01-29 Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
WO2019079347A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. USES OF BASIC EDITORS ADENOSINE
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
EP3794130A4 (en) 2018-05-16 2022-07-27 Synthego Corporation METHODS AND SYSTEMS FOR DESIGNING AND USING GUIDE RNA
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
DE112020001342T5 (de) 2019-03-19 2022-01-13 President and Fellows of Harvard College Verfahren und Zusammensetzungen zum Editing von Nukleotidsequenzen
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2021072328A1 (en) 2019-10-10 2021-04-15 The Broad Institute, Inc. Methods and compositions for prime editing rna
GB2614813B (en) 2020-05-08 2025-05-07 Harvard College Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
EP4179085A1 (en) * 2020-07-07 2023-05-17 Oriengene Biotechnology Ltd Guide rna for hsv-1 gene editing and method thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150098954A1 (en) * 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2016196273A1 *
YANWEI BI ET AL: "High-Efficiency Targeted Editing of Large Viral Genomes by RNA-Guided Nucleases", PLOS PATHOGENS, vol. 10, no. 5, 1 May 2014 (2014-05-01), pages e1004090, XP055198358, DOI: 10.1371/journal.ppat.1004090 *

Also Published As

Publication number Publication date
CA3000189A1 (en) 2016-12-08
WO2016196273A1 (en) 2016-12-08
EP3331571A1 (en) 2018-06-13
JP2018516983A (ja) 2018-06-28

Similar Documents

Publication Publication Date Title
EP3331571A4 (en) COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS
EP3139954A4 (en) Methods and compositions for treating hepatitis b virus infections
IL251527B (en) Preparations of adenosine deaminase-2 (ada2), their variants and methods of using them
EP3325620A4 (en) ANTIVIRAL PROCEDURES AND COMPOSITIONS
EP3240787A4 (en) Derivatives and methods of treating hepatitis b infections
EP3145493A4 (en) Methods and compositions relating to exosomes
EP3262559A4 (en) System and method to mitigate malware
EP3256113A4 (en) Treatment of hypoparathyroidism
EP3102670A4 (en) Systems, methods, and compositions relating to combiomics
EP3134130A4 (en) Compositions and methods to treating hemoglobinopathies
SG11201707876YA (en) Microalgal compositions and uses thereof
EP3166593A4 (en) Topical antiviral compositions and methods of using the same
EP3207048A4 (en) Compositions and methods of treating muscular dystrophy
EP3157565A4 (en) Treatment of polybacterials infections
EP3512524A4 (en) METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS
EP3139928A4 (en) Anordrin compositions and methods for treating diseases
EP3307330A4 (en) Method of treatment using oncolytic viruses
EP3253389A4 (en) Apilimod compositions and methods for using same
EP3250553A4 (en) Compositions and methods for inhibiting viral infection
EP3642415A4 (en) NANOLIGNOCELLULOSE COMPOSITIONS AND THEIR PRODUCTION PROCESSES
EP3253211A4 (en) Compositions and methods for treatment of edema
EP3166637A4 (en) Compositions and methods for treating dengue virus infection
EP3204426A4 (en) Compositions and methods for treating viral hemorrhagic fever
EP3310382A4 (en) Compositions and methods for modulating viral infection
EP3250550A4 (en) Compositions and methods for viral sensitization

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20180416

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AGENOVIR CORPORATION

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190308

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 48/00 20060101AFI20190304BHEP

Ipc: A61K 9/08 20060101ALI20190304BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1255580

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20191008